Thelansis

  Acral Lentiginous Melanoma (ALM) Market Outlook Thelansis’s “Acral Lentiginous Melanoma (ALM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acral Lentiginous Melanoma (ALM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Acral Lentiginous Melanoma (ALM) Overview Acral lentiginous melanoma (ALM), a rare form of skin cancer, occurs equally across all ethnicities and carries a poorer prognosis compared to other melanoma types. It typically manifests as dark, irregular patches, bumps, or lumps on the feet, and less frequently on the hands. Histologically, acral lentiginous melanoma presents with an asymmetrical, poorly defined ...

  Acral lentiginous melanoma (ALM), a rare form of skin cancer, occurs equally across all ethnicities and carries a poorer prognosis compared to other melanoma types. It typically manifests as dark, irregular patches, bumps, or lumps on the feet and less frequently on the hands. Histologically, acral lentiginous melanoma presents with an asymmetrical, poorly defined proliferation of individual melanocytes along the junction between the dermis and epidermis, with single melanocytes being more prevalent than clusters. Differential diagnosis from benign acral lentiginous nevi, which may exhibit localized abnormalities, is crucial. Surgical management is challenging due to the intricate nature and functional importance of the affected extremities, often necessitating reconstructive procedures post-resection. Prognosis depends on the disease stage, generally proving worse compared to other melanoma subtypes, often diagnosed in the sixth or seventh decade of life. Clinically,...